Literature DB >> 31420405

Authors' Reply.

Yusuke Sakaguchi1, Takayuki Hamano2, Atsushi Wada1, Ikuto Masakane1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31420405      PMCID： PMC6727257          DOI： 10.1681/ASN.2019050550

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  5 in total

1.  Equivalent Doses Matter, Rather Than Types.

Authors:  Norio Hanafusa; Ken Tsuchiya
Journal:  J Am Soc Nephrol       Date:  2019-08-16       Impact factor: 10.121

2.  ESA Resistance May Be a Potential Confounder for Mortality among Different ESA Types.

Authors:  Mototsugu Tanaka; Kayo Shinohara; Akiko Ono; Mutsuhiro Ikuma
Journal:  J Am Soc Nephrol       Date:  2019-08-16       Impact factor: 10.121

3.  Analysis of Other Confounding Factors Is Mandatory before Considering That Long-Acting Erythropoiesis Stimulating Agents Are Deleterious to Patients on Dialysis.

Authors:  Guy Rostoker; Fanny Lepeytre; Jacques Rottembourg
Journal:  J Am Soc Nephrol       Date:  2019-08-16       Impact factor: 10.121

4.  Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Atsushi Wada; Ikuto Masakane
Journal:  J Am Soc Nephrol       Date:  2019-04-23       Impact factor: 10.121

5.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.